Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Aromatase Inhibitors Clear all
Completed No phase listed Observational

Oral Aromatase Inhibitors Modify the Gut Microbiome

NCT05030038
View directory record Official record
Conditions
Breast Cancer
Interventions
Fecal swab collection, Blood samples
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

NCT02820961
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
entinostat, exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 5, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors

NCT03707340
View directory record Official record
Conditions
Breast Cancer, Hyposexual Desire Disorder
Interventions
Flibanserin Pill
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Not applicable Interventional

The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.

NCT02057536
View directory record Official record
Conditions
Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness
Interventions
Arm A Directed exercise program, Observation
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
40 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 5, 2026, 5:54 AM EDT
Not yet recruiting Phase 4 Interventional

Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors

NCT07769047
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Functional Assessment, Lifestyle Counseling, Semaglutide
Procedure · Other · Behavioral + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 55 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

NCT00365599
View directory record Official record
Conditions
Breast Cancer
Interventions
suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
8
States / cities
San Francisco, California • Boynton Beach, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 5, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

NCT02738866
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2Phase 3 Interventional

Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys

NCT00133354
View directory record Official record
Conditions
Hypopituitarism
Interventions
Arimidex (Anastrozole), Placebo, Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 18 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Letrozole as a Treatment of Endometrial Cancer

NCT00997373
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
Letrozole
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
40 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

NCT02437318
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Alpelisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
34
States / cities
Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 5, 2026, 5:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors

NCT00954564
View directory record Official record
Conditions
Arthralgia, Breast Cancer
Interventions
aromatase inhibition therapy - OBSERVATIONAL ONLY, medical chart review, questionnaire administration, assessment of therapy complications
Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years to 90 Years · Female only
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors

NCT01509079
View directory record Official record
Conditions
Muscle Pain, Joint Pain
Interventions
Vitamin D3
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

NCT01797120
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, Everolimus, Placebo
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
25
States / cities
Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 5, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention

NCT03739983
View directory record Official record
Conditions
Adherence, Medication
Interventions
Vaginal Renewal Program
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

NCT00508586
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
PTC299
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

NCT03477396
View directory record Official record
Conditions
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Aromatase Inhibitor, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration, Ribociclib
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
70 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
9
States / cities
Corona, California • Duarte, California • Lancaster, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 5, 2026, 5:54 AM EDT
Completed No phase listed Observational

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms

NCT02874222
View directory record Official record
Conditions
Breast Cancer
Interventions
surveys completed by subject
Other
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 60 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 5, 2026, 5:54 AM EDT
Active, not recruiting Phase 3 Interventional

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557
View directory record Official record
Conditions
Breast Cancer, Early Breast Cancer
Interventions
Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
111
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

NCT07541079
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Giredestrant
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Fountain Valley, California • Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

NCT02236572
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Altering Lipids for Tolerance of Aromatase Inhibitor Therapy

NCT04268134
View directory record Official record
Conditions
Breast Cancer
Interventions
Omega-3 fatty acid supplement
Dietary Supplement
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

NCT03518138
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
Q-122, Placebo
Drug
Lead sponsor
Que Oncology
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Woodstock, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 5, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

NCT03439735
View directory record Official record
Conditions
Breast Cancer
Interventions
Endocrine Therapy and a CDK 4/6 inhibitor
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 5, 2026, 5:54 AM EDT